Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Cranberries & UTIs

This article was originally published in The Tan Sheet

Executive Summary

NCCAM calls for supplies of cranberry juice cocktail, concentrate and encapsulated powders, with matching placebos, in Request For Information posted on center's Web site. Collected cranberry products will be used in "NIH-supported research, specifically (but not exclusively) for basic and clinical research on the role of cranberry (Vaccinium macrocarpon) in the prevention and treatment of urinary tract infections." Request marks an initial step in cranberry initiative approved at NCCAM's advisory council meeting Aug. 27 (1"The Tan Sheet" Sept. 3, p. 4)

You may also be interested in...

NCCAM Slowing Research Pace, Turning To Program Announcements

The National Center for Complementary & Alternative Medicine will issue proportionately more program announcements (PAs) in the coming year than requests for applications (RFAs), hedging against a possible upsurge of out-year costs for funded grants.

People In Brief

Perrigo promotes in pricing, planning

In Brief

Combe sells most of its OTC brands





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts